| Literature DB >> 30691028 |
Ryan da Silva Ramos1,2,3, Josivan da Silva Costa4,5, Rai Campos Silva6,7, Glauber Vilhena da Costa8, Alex Bruno Lobato Rodrigues9,10, Érica de Menezes Rabelo11, Raimundo Nonato Picanço Souto12, Carlton Anthony Taft13, Carlos Henrique Tomich de Paula da Silva14,15, Joaquín Maria Campos Rosa16, Cleydson Breno Rodrigues Dos Santos17,18,19, Williams Jorge da Cruz Macêdo20,21,22.
Abstract
Aedes aegypti is the main vector of dengue fever transmission, yellow fever, Zika, and chikungunya in tropical and subtropical regions and it is considered to cause health risks to millions of people in the world. In this study, we search to obtain new molecules with insecticidal potential against Ae. aegypti via virtual screening. Pyriproxyfen was chosen as a template compound to search molecules in the database Zinc_Natural_Stock (ZNSt) with structural similarity using ROCS (rapid overlay of chemical structures) and EON (electrostatic similarity) software, and in the final search, the top 100 were selected. Subsequently, in silico pharmacokinetic and toxicological properties were determined resulting in a total of 14 molecules, and these were submitted to the PASS online server for the prediction of biological insecticide and acetylcholinesterase activities, and only two selected molecules followed for the molecular docking study to evaluate the binding free energy and interaction mode. After these procedures were performed, toxicity risk assessment such as LD50 values in mg/kg and toxicity class using the PROTOX online server, were undertaken. Molecule ZINC00001624 presented potential for inhibition for the acetylcholinesterase enzyme (insect and human) with a binding affinity value of -10.5 and -10.3 kcal/mol, respectively. The interaction with the juvenile hormone was -11.4 kcal/mol for the molecule ZINC00001021. Molecules ZINC00001021 and ZINC00001624 had excellent predictions in all the steps of the study and may be indicated as the most promising molecules resulting from the virtual screening of new insecticidal agents.Entities:
Keywords: PASS; acetylcholinesterase; juvenile hormone; molecular docking
Year: 2019 PMID: 30691028 PMCID: PMC6469432 DOI: 10.3390/ph12010020
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 12D structural formula of pyriproxyfen (2-[1-methyl-2-(4-phenoxyphenoxy) ethoxy] pyridine).
Pharmacokinetic properties of selected molecules.
| Molecules | a Star | b CNS | c MW | d QP logKp | e HBD | f HBA | g R5 | h R3 |
|---|---|---|---|---|---|---|---|---|
| Normal range | 0–5 | −2 to +2 | <500 | −8 to −1 | <5 | <10 | Max. 4 | Max. 3 |
| Pyriproxyfen | 1 | 1 | 321.4 | 0.8 | 0 | 4 | 1 | 0 |
| ZINC11616655 | 0 | 0 | 376.5 | −1.6 | 1 | 3 | 0 | 1 |
| ZINC13537284 | 0 | 0 | 294.4 | −1.7 | 2 | 5 | 0 | 0 |
| ZINC00073711 | 0 | 1 | 201.2 | −1.8 | 1 | 3 | 0 | 0 |
| ZINC00001021 | 0 | 0 | 212.2 | −0.6 | 0 | 2 | 0 | 0 |
| ZINC11616399 | 0 | 0 | 384.5 | −2.3 | 0 | 4 | 0 | 1 |
| ZINC01530753 | 0 | 1 | 356.1 | −2.3 | 0 | 4 | 0 | 0 |
| ZINC01530718 | 0 | 1 | 267.4 | −3.0 | 3 | 4 | 0 | 0 |
| ZINC11616398 | 0 | 0 | 384.5 | −2.2 | 0 | 4 | 0 | 1 |
| ZINC00000257 | 0 | 0 | 295.4 | −4.1 | 1 | 4 | 0 | 0 |
| ZINC04363405 | 0 | 0 | 414.6 | −2.9 | 0 | 4 | 0 | 1 |
| ZINC03831238 | 0 | 0 | 299.4 | −3.3 | 4 | 3 | 0 | 0 |
| ZINC12504271 | 0 | 0 | 366.8 | −2.4 | 0 | 3 | 0 | 1 |
| ZINC00538483 | 0 | 1 | 371.9 | −3.4 | 1 | 6 | 0 | 0 |
| ZINC00001624 | 0 | 1 | 337.5 | −2.9 | 2 | 3 | 0 | 0 |
[a] Number of computed properties which fall outside the required range for 95% of known drug; [b] activity in the central nervous system; [c] molar weight; [d] the predicted skin permeability; [e] number of hydrogen bonds donated by the molecule; [f] number of hydrogen bonds accepted by the molecule; [g] number of violations of Lipinski’s ‘rule of five’; [h] number of violations of Jorgensen’s ‘rule of three’.
Predictions of the toxicological properties of molecules.
| Molecules | Prediction | Alert |
|---|---|---|
| Pyriproxyfen | - | No alert |
| ZINC11616655 | Hepatotoxicity | Plausible |
| Skin sensitization | ||
| Teratogenicity | ||
| Estrogenicity | ||
| ZINC13537284 | - | No alert |
| ZINC00073711 | Hepatotoxicity | Plausible |
| Teratogenicity | ||
| ZINC00001021 | - | No alert |
| ZINC11616399 | Hepatotoxicity | Plausible |
| Skin sensitization | ||
| Teratogenicity | ||
| Estrogenicity | ||
| ZINC01530753 | Carcinogenicity | Plausible |
| Chromosome damage | ||
| Skin sensitization | ||
| ZINC01530718 | - | No alert |
| ZINC11616398 | Hepatotoxicity | Plausible |
| Skin sensitization | ||
| Teratogenicity | ||
| Estrogenicity | ||
| ZINC00000257 | - | No alert |
| ZINC04363405 | Skin sensitization | Plausible |
| ZINC03831238 | hERG channel inhibition | Plausible |
| Skin sensitization | ||
| ZINC12504271 | Skin sensitization | Plausible |
| ZINC00538483 | hERG channel inhibition | Plausible |
| Skin sensitization | ||
| ZINC00001624 | - | No alert |
Figure 22D structures of selected molecules with good pharmacokinetic and toxicological profiles.
Biological activity prediction of the compounds selected by virtual screening.
| Molecules | Pa a | Pi b | Biological Activity |
|---|---|---|---|
| Pyriproxyfen | 0.586 | 0.003 | Insecticide |
| I40 | 0.025 | 0.005 | Acetylcholine transporter inhibitor |
| GNT | 0.376 | 0.154 | Acetylcholine neuromuscular blocking agent |
| JHIII | 0.336 | 0.011 | Insecticide |
| ZINC13537284 | - | - | - |
| ZINC00001021 | 0.444 | 0.005 | Insecticide |
| ZINC01530718 | - | - | - |
| ZINC00000257 | - | - | - |
| ZINC00001624 | 0.450 | 0.005 | Acetylcholine antagonist |
| 0.433 | 0.044 | Acetyl esterase inhibitor |
a Pa = probability to be active; b Pi = probability to be inactive.
Figure 3Superpositions of crystallographic ligands poses (in green) with the calculated poses (in red): (A) I40, (B) GNT, and (C) JHIII.
Figure 4Results of binding affinity of the compounds with insect acetylcholinesterase (Drosophila melanogaster organism), Protein Data Bank (PDB) ID 1QON.
Figure 5Results of binding affinity of the compounds with human acetylcholinesterase (hAChE), PDB ID 4EY6.
Figure 6Results of binding affinity of the compounds with the juvenile hormone (PDB ID 5V13).
Figure 7Interactions between the acetylcholinesterase active site and the compounds ZINC00001021 (A) and ZINC00001624 (B).
Figure 8Active site interactions between the human acetylcholinesterase active site and the molecules ZINC00001021 (A) and ZINC00001624 (B).
Figure 9Interactions between the active site of juvenile hormone with the molecules ZINC00001021 (A) and ZINC00001624 (B).
Oral toxicity prediction results for input compound.
| Molecules | Predicted LD50 (mg/kg) | Predicted Toxicity Class [a] |
|---|---|---|
| Pyriproxyfen (Control) | 2000 | IV |
| I40 | 200 | III |
| GNT | 19 | II |
| JHIII | 5000 | IV |
| ZINC00001021 | 1000 | IV |
| ZINC00001624 | 349 | III |
[a] Class I: fatal if swallowed (LD50 ≤ 5); Class II: fatal if swallowed (5 < LD50 ≤ 50); Class III: toxic if swallowed (50 < LD50 ≤ 300); Class IV: harmful if swallowed (300 < LD50 ≤ 2000); Class V: may be harmful if swallowed (2000 < LD50 ≤ 5000); Class VI: non-toxic (LD50 > 5000).
Figure 10Promising molecules ZINC00001021 (1) and ZINC00001624 (2) obtained after virtual screening.
Figure 11Structures of the AChE inhibitors, 9-(3-iodobenzylamino)-1,2,3,4-tetrahydroacridine (I40), (−)-galanthamine (GNT) and methyl(2E,6E)-9-[(2R)-3,3-dimethyloxiran-2-yl]-3,7-dimethylnona-2,6-dienoate (JHIII), used in the present work.
Data from protocols used here for molecular docking validation.
| Enzyme | Inhibitor | Coordinates of the Grid Center | Grid Size (Points) |
|---|---|---|---|
| AChE | 9-(3-Iodobenzylamino)-1,2,3,4-Tetrahydroacridine | X = 33.4862 | 35 x |
| AChE | (−)-galanthamine | X = 9.090 | 32 x |
| Juvenile hormone | methyl (2E,6E)-9-[(2R)-3,3-dimethyloxiran-2-yl]-3,7-dimethylnona-2,6-dienoate | X = −213.788 | 40 x |